EMA Application withdrawn: Restaysis (ciclosporin) — Allergan Pharmaceuticals International Limited

View source ↗

Summary

The EMA withdrew the application for Restaysis (ciclosporin) by Allergan for dry eye syndromes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Syndromes

Drugs mentioned

• Restaysis (ciclosporin)

Snippet

Status: Application withdrawn. Therapeutic area: Dry Eye Syndromes. MAH: Allergan Pharmaceuticals International Limited. Decision date: 01/06/2018